CPHI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPHI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of -3.18 is in distress zone. This implies bankruptcy possibility in the next two years.
China Pharma Holding has a Altman Z-Score of -3.20, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for China Pharma Holding's Altman Z-Score or its related term are showing as below:
During the past 13 years, China Pharma Holding's highest Altman Z-Score was 0.85. The lowest was -3.93. And the median was -0.78.
The historical data trend for China Pharma Holding's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Altman Z-Score | Get a 7-Day Free Trial | -3.93 | -1.22 | -1.23 | -3.19 | -3.10 |
China Pharma Holding Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Altman Z-Score | Get a 7-Day Free Trial | -3.19 | -3.30 | -3.56 | -3.37 | -3.10 |
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
China Pharma Holding's Altman Z-Score for today is calculated with this formula:
Z | = | 1.2 | * | X1 | + | 1.4 | * | X2 | + | 3.3 | * | X3 | + | 0.6 | * | X4 | + | 1.0 | * | X5 |
= | 1.2 | * | -0.05 | + | 1.4 | * | -2.3857 | + | 3.3 | * | -0.1667 | + | 0.6 | * | 0.5358 | + | 1.0 | * | 0.4257 | |
= | -3.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $16.47 Mil.
Total Current Assets was $6.00 Mil.
Total Current Liabilities was $6.82 Mil.
Retained Earnings was $-39.29 Mil.
Pre-Tax Income was -1.232 + -0.778 + -0.593 + -0.476 = $-3.08 Mil.
Interest Expense was -0.05 + -0.066 + -0.138 + -0.079 = $-0.33 Mil.
Revenue was 2.15 + 1.803 + 1.098 + 1.96 = $7.01 Mil.
Market Cap (Today) was $4.83 Mil.
Total Liabilities was $9.02 Mil.
* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.
X1 | = | Working Capital | / | Total Assets |
= | (Total Current Assets - Total Current Liabilities) | / | Total Assets | |
= | (5.997 - 6.821) | / | 16.469 | |
= | -0.05 |
X2 | = | Retained Earnings | / | Total Assets |
= | -39.29 | / | 16.469 | |
= | -2.3857 |
X3 | = | Earnings Before Interest and Taxes | / | Total Assets |
= | (Pre-Tax Income - Interest Expense) | / | Total Assets | |
= | (-3.079 - -0.333) | / | 16.469 | |
= | -0.1667 |
X4 | = | Market Value Equity | / | Book Value of Total Liabilities |
= | Market Cap | / | Total Liabilities | |
= | 4.830 | / | 9.015 | |
= | 0.5358 |
X5 | = | Revenue | / | Total Assets |
= | 7.011 | / | 16.469 | |
= | 0.4257 |
The zones of discrimination were as such:
Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones
China Pharma Holding has a Altman Z-Score of -3.20 indicating it is in Distress Zones.
Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.
China Pharma Holding (OTCPK:CPHI) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Read more about Altman Z-Score and the original research.
Be Aware
Altman Z-Score does not apply to financial companies.
Thank you for viewing the detailed overview of China Pharma Holding's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Ke Deng | 10 percent owner | NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216 |
Frank Waung | officer: Chief Financial Officer | 72 GREAT HILLS RD., SHORT HILLS NJ 07078 |
G Michael Bennett | director | 4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600 |
Yingwen Zhang | director | NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041 |
Baowen Dong | director | NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041 |
Heung Mei Tsui | director, 10 percent owner | FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX |
Zhilin Li | officer: President and CEO | 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216 |
Jian Yang | officer: Secretary | NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216 |
Xinhua Wu | officer: CFO | 2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216 |
George L Diamond | 10 percent owner | 174 FM 1830, ARGYLE TX 76226 |
David F Brigante | 10 percent owner | 174FM 1830, ARGYLE TX 76226 |
Marat Rosenberg | 10 percent owner | 17 FM 1830, ARGYLE TX 76226 |
Halter Financial Investments Lp | 10 percent owner | 174 FM 1830, ARGYLE TX 76226 |
Halter Financial Investments Gp Llc | 10 percent owner | 174 FM 1830, ARGYLE TX 76226 |
Timothy P Halter | director, 10 percent owner, officer: CEO, President & CFO | 174 FM 1830, ARGYLE TX 76226 |
From GuruFocus
By PRNewswire PRNewswire • 05-15-2019
By PRNewswire • 08-09-2023
By PRNewswire PRNewswire • 03-02-2020
By PRNewswire PRNewswire • 06-22-2022
By PRNewswire PRNewswire • 11-15-2018
By PRNewswire PRNewswire • 12-02-2022
By PRNewswire PRNewswire • 07-02-2022
By PRNewswire PRNewswire • 03-29-2019
By PRNewswire PRNewswire • 03-13-2020
By PRNewswire PRNewswire • 12-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.